<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-88948</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Efficacy and safety of ezetimibe in vascular risk units</dc:title>
<dc:description xml:lang="en">Objectives. This study was intended to assess the efficacy and safety of ezetimibe when taken alone or combined with statins in a specialized care setting and under standard clinical practice conditions. Patients and methods. A multicenter, retrospective study in patients with dyslipidemia seen in a specialized outpatient clinic and treated with ezetimibe for at least 12weeks. Patients were divided into three groups: monotherapy, add-on ezetimibe, and initial coadministration. Results. A total of 217 patients (mean age 59years; 37% ¡Ý65years) were enrolled. Of these, 61% were women, 21% had type 2 diabetes and 20% had had a previous cardiovascular event so that the lipid lower drug treatment should satisfy the objectives of secondary prevention. Mean change in the monotherapy group (n=92; mean 41weeks) included: decrease of LDLc of 28% (P&lt;.001). In the group where ezetimibe was added on to different ongoing statins (n=94, mean 73weeks), mean changes was as follows: LDLc ¨C34%, significant change as compared to monotherapy (P&lt;.001). In the group with initial coadministration of ezetimibe with different statins (n=31; mean 118weeks), mean change included: LDLc ¨C53% (P&lt;.001). Overall, 64% of patients reached the thereapeutic objective proposed for the Adult Treatment Panel III (ATPIII) for cLDL. In patients with low risk (LDLc&lt;160mg/dL), moderate risk (LDLc&lt;130mg/dL) and high-very high risk (LDLc&lt;100-70mg/dL), the percentage of patients who reached the therapeutic objective was 81%, 64% and 44%, respectively. Conclusions. Under standard clinical practice conditions, ezetimibe appears to be effective and safe for the control LDLc, thus making it possible to reach the therapeutic objectives proposed by the ATP-III in a high number of patients, especially when associated to statins(AU)</dc:description>
<dc:creator>Su¨¢rez Tembra, M</dc:creator>
<dc:creator>D¨ªaz Peromingo, J. A</dc:creator>
<dc:creator>Mart¨ªnez Ramonde, T</dc:creator>
<dc:creator>Pose Reino, A</dc:creator>
<dc:creator>D¨ªaz D¨ªaz, J. L</dc:creator>
<dc:creator>Pena Seijo, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos. Desconocemos la eficacia hipolipemiante y la seguridad de ezetimiba en monoterapia o combinada con estatinas en atenci¨®n especializada y condiciones de pr¨¢ctica cl¨ªnica. Pacientes y m¨¦todos. Estudio retrospectivo multic¨¦ntrico (unidades hospitalarias de medicina interna y endocrinolog¨ªa) de pacientes tratados con ezetimiba durante al menos 12 semanas. Los pacientes fueron incluidos en tres grupos: a) ezetimiba como ¨²nico hipolipemiante; b) ezetimiba a&amp;ntilde;adida a estatina, y c) ezetimiba combinada de inicio con estatina. La variable principal fue el porcentaje medio de reducci¨®n de colesterol de las lipoprote¨ªnas de baja densidad (cLDL) en el ¨²ltimo an¨¢lisis disponible respecto al documentado antes de comenzar el tratamiento con ezetimiba. Resultados. Incluimos a 217 pacientes (media de edad, 59 a&amp;ntilde;os), 61% mujeres. Un 21% padec¨ªa diabetes mellitus tipo 2 y el 20% hab¨ªa sufrido un evento cardovascular previo, por lo que el tratamiento hipolipemiante deb¨ªa satisfacerr objetivos de prevenci¨®n secundaria. En el subgrupo de monoterapia (n=92; tratamiento medio, 41 semanas) el cLDL descendi¨® un 28% (p&lt;0,001). En el subgrupo de ezetimiba a&amp;ntilde;adido a estatinas (n=94; tratamiento medio, 73 semanas) el cLDL disminuy¨® un 34% (p&lt;0,001). En el subgrupo ezetimiba m¨¢s estatina de inicio (n=31; tratamiento medio, 118 semanas) el cLDL descendi¨® un 53% (p&lt;0,001). En total, un 64% de los pacientes alcanz¨® el objetivo terap¨¦utico propuesto por el Adult Treatment Panel III (ATPIII) para cLDL. En los pacientes con bajo riesgo (cLDL&lt;160 mg/dl), riesgo moderado (cLDL&lt;130 mg/dl) y riesgo alto-muy alto (cLDL&lt;100-70 mg/dl), los enfermos en objetivo terap¨¦utico fueron el 81%, el 64% y el 44%, respectivamente. Conclusiones. En condiciones de pr¨¢ctica cl¨ªnica habitual, ezetimiba resulta eficaz y segura para reducir el cLDL, permitiendo alcanzar los objetivos terap¨¦uticos propuestos por ATPIII en un elevado n¨²mero de pacientes, especialmente si se combina con estatinas(AU)</dc:description>
<dc:source>Rev Clin Esp;211(6): 283-290, jun.2011.</dc:source>
<dc:identifier>ibc-88948</dc:identifier>
<dc:title xml:lang="es">Eficacia y seguridad de ezetimiba en unidades de riesgo vascular</dc:title>
<dc:subject>^d3946^s22012</dc:subject>
<dc:subject>^d8251^s22002</dc:subject>
<dc:subject>^d931^s22073</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d931^s22002</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d2834^s22002</dc:subject>
<dc:subject>^d2359^s22012</dc:subject>
<dc:subject>^d7130^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d28570^s22066</dc:subject>
<dc:subject>^d2359^s22080</dc:subject>
<dc:subject>^d7130^s22012</dc:subject>
<dc:subject>^d2834^s22044</dc:subject>
<dc:subject>^d2359^s22054</dc:subject>
<dc:subject>^d7130^s22054</dc:subject>
<dc:subject>^d53393</dc:subject>
<dc:subject>^d8251^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:type>article</dc:type>
<dc:date>201106</dc:date>
</metadata>
</record>
</ibecs-document>
